Benzinga | Aug 5, 2021 04:37PM EDT

Spero Therapeutics Q2 EPS $(0.63) Beats $(0.77) Estimate, Sales $5.15M Beat $4.03M Estimate

Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.77) by 18.18 percent. This is a 25.88 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $5.15 million which beat the analyst consensus estimate of $4.03 million by 27.74 percent. This is a 198.09 percent increase over sales of $1.73 million the same period last year.